NIHR-Supported Trial Shows New Nasal Vaccine Could Improve Whooping Cough Protection

A human challenge trial backed by the National Institute for Health and Care Research (NIHR) suggests that a new nasal vaccine, BPZE1, could offer superior protection against whooping cough. The study, conducted at the NIHR Southampton Biomedical Research Centre and Clinical Research Facility, involved 53 adult volunteers exposed to the bacteria in a controlled setting. Results, published in The Lancet Microbe, showed that BPZE1 prevented bacterial colonization in the nose and throat and triggered strong immune responses, indicating potential for long-lasting protection.

Whooping cough cases in England reached a 30-year high in 2024, with 14,879 infections and 11 infant deaths. Unlike existing vaccines, which mainly protect infants via maternal immunity, BPZE1 could reduce transmission and protect both children and adults. Phase 3 trials are planned for 2026.

08-12-2025